These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8829314)

  • 21. Outpatient management of febrile neutropenia in children with cancer.
    Holdsworth M; Hanrahan J; Albanese B; Frost J
    Paediatr Drugs; 2003; 5(7):443-55. PubMed ID: 12837117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefepime monotherapy for treatment of febrile neutropenia in children.
    Ariffin H; Ai CL; Lee CL; Abdullah WA
    J Paediatr Child Health; 2006 Dec; 42(12):781-4. PubMed ID: 17096713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia?
    Karthaus M; Carratalà J; Jürgens H; Ganser A
    Chemotherapy; 1998; 44(6):427-35. PubMed ID: 9755304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proceedings of the 4th International Symposium on Febrile Neutropenia. December 15-17, 1999.
    Int J Antimicrob Agents; 2000 Oct; 16(2):83-187. PubMed ID: 11203263
    [No Abstract]   [Full Text] [Related]  

  • 25. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
    Paganini H; Rodriguez-Brieshcke T; Zubizarreta P; Latella A; Firpo V; Casimir L; Armada A; Fernández C; Cáceres E; Debbag R
    Cancer; 2001 Apr; 91(8):1563-7. PubMed ID: 11301406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.
    Karaman S; Vural S; Yildirmak Y; Emecen M; Erdem E; Kebudi R
    Pediatr Blood Cancer; 2012 Apr; 58(4):579-83. PubMed ID: 21674768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia.
    Ichikawa M; Suzuki D; Ohshima J; Cho Y; Kaneda M; Iguchi A; Ariga T
    Pediatr Blood Cancer; 2011 Dec; 57(7):1159-62. PubMed ID: 21438131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fever and granulocytopenia: a viewpoint from an academic setting.
    Vogelzang NJ; Flaherty JP
    Recent Results Cancer Res; 1993; 132():79-88. PubMed ID: 8265873
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fever and neutropenia in children with malignant disease.
    Roguin A; Kasis I; Ben-Arush MW; Sharon R; Berant M
    Pediatr Hematol Oncol; 1996; 13(6):503-10. PubMed ID: 8940733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controversies in new antibiotic therapy for ambulatory patients.
    Sundararajan V; Rubenstein EB; Rolston KV; Elting LS
    Support Care Cancer; 1997 Sep; 5(5):358-64. PubMed ID: 9322346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment and treatment of low-risk febrile neutropenic (LRFN) pediatric patients with cancer.
    Zubizarreta P; Paganini H
    Med Pediatr Oncol; 2002 Apr; 38(4):292. PubMed ID: 11920803
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.
    Dranitsaris G
    Pharmacoeconomics; 1999 Oct; 16(4):343-53. PubMed ID: 10623363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Febrile neutropenia: are you up to date?
    West P
    Can Oncol Nurs J; 2003; 13(4):246-9. PubMed ID: 14692367
    [No Abstract]   [Full Text] [Related]  

  • 35. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is monotherapy for febrile neutropenia still a viable alternative?
    Ramphal R
    Clin Infect Dis; 1999 Sep; 29(3):508-14. PubMed ID: 10530437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monotherapy versus combination therapy for febrile neutropenia.
    Ramphal R
    Int J Hematol; 1998 Oct; 68 Suppl 1():S21-5. PubMed ID: 9838740
    [No Abstract]   [Full Text] [Related]  

  • 39. [Empirical treatment of fever and neutropenia: rationalization of antimicrobial schemes in the patient with cancer].
    Santos JI
    Bol Med Hosp Infant Mex; 1989 Dec; 46(12):759-60. PubMed ID: 2627270
    [No Abstract]   [Full Text] [Related]  

  • 40. Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours.
    Kutluk T; Kurne O; Akyüz C; Ceyhan M; Kanra G; Büyükpamukçu M; Seçmeer G
    Pediatr Blood Cancer; 2004 Mar; 42(3):284-6. PubMed ID: 14752869
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.